Is AOD-9604 Legal in South Carolina? How Women Can Access It

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176 to 191 of human growth hormone (hGH). Researchers at Monash University in Australia isolated this region of the hGH molecule specifically because it appeared to drive fat metabolism without the insulin-desensitizing or cell-proliferating effects of the full hormone. The "AOD" stands for Anti-Obesity Drug.

The compound works by mimicking the way endogenous growth hormone stimulates lipolysis and inhibits lipogenesis, primarily through beta-3 adrenergic receptor activity in adipose tissue. Because it lacks the full hGH receptor-binding domain, it does not raise IGF-1 levels in the dose ranges studied, which is the main theoretical safety advantage over full-length growth hormone.

Why Women Ask About It

For women managing weight through perimenopause and postmenopause, the drop in endogenous growth hormone secretion is real and measurable. Pituitary growth hormone pulse amplitude declines significantly with age and estrogen withdrawal, which contributes to the central adiposity pattern many women notice in their 40s and 50s. AOD-9604 is marketed as a targeted way to address this without systemic hGH therapy.

Women with PCOS also ask about it because visceral fat and insulin resistance are core features of PCOS, and some providers frame AOD-9604 as an adjunct to metabolic management. The evidence base for that specific use does not yet exist.

The One Human Trial You Should Know

The most-cited human study is a Phase IIb randomized controlled trial by Heffernan et al. Published in 2001, which tested multiple AOD-9604 doses against placebo in adults with obesity over 12 weeks. The 1 mg daily subcutaneous dose produced statistically significant fat mass reduction compared to placebo. That trial enrolled both men and women, but sex-stratified results were not published separately. This is the evidence gap women deserve to know about: no trial has reported outcomes specifically in women, in women with PCOS, or in postmenopausal women.

Federal Legal Status: The FDA Framework You Need to Understand

AOD-9604 is not approved by the FDA as a drug. That single fact shapes every legal question that follows.

What the FDA Bulk Substances Lists Mean

Compounding pharmacies in the United States operate under two regulatory tracks created by the Drug Quality and Security Act of 2013. Section 503A covers traditional pharmacies that compound for individual patients on a prescription basis. Section 503B covers outsourcing facilities that produce larger sterile batches without individual prescriptions.

The FDA maintains a "bulk drug substances" list for each track. A substance on the 503A list can be used by a compounding pharmacy to fill a patient-specific prescription. A substance on the 503B list can be used by an outsourcing facility.

In 2016, the FDA removed AOD-9604 from the 503B bulks list, meaning licensed outsourcing facilities may not compound it for office stock or wholesale distribution. This is the action that created the current gray zone.

What the 503A Situation Looks Like Now

The FDA has not placed AOD-9604 on its 503A "do not compound" list (the Demonstrably Difficult to Compound or clinical need negative lists). The FDA's 503A bulk substances evaluation process is ongoing, and AOD-9604 has not received a final negative determination under that track.

The practical consequence: a 503A-compliant compounding pharmacy can currently compound AOD-9604 for an individual patient if a licensed prescriber writes a valid patient-specific prescription. This is the legal access path that exists right now. It is not guaranteed to remain open if the FDA issues a negative 503A determination in the future.

Research-Chemical Gray Zone

Some online vendors sell AOD-9604 labeled "for research use only" and not for human use. Purchasing this product and self-administering it is not a legal prescription pathway. It bypasses quality controls, sterility testing, and endotoxin limits that compounding pharmacies are required to meet. Women should not use research-chemical sources.

South Carolina State Law: What Actually Exists

South Carolina does not have a state statute that specifically names AOD-9604 or bans peptide prescribing. The relevant state frameworks are:

The South Carolina Pharmacy Practice Act

The South Carolina Pharmacy Practice Act (Title 40, Chapter 43 of the SC Code of Laws) governs compounding in the state. SC-licensed pharmacies that compound sterile preparations must comply with USP 797 standards for sterile compounding and are subject to inspection by the South Carolina Department of Labor, Licensing and Regulation (LLR). A 503A pharmacy operating in SC or shipping to a SC patient from another state must hold the appropriate license.

No provision of the South Carolina Pharmacy Practice Act specifically prohibits compounding AOD-9604.

The South Carolina Medical Practice Act

Licensed physicians, nurse practitioners, and physician assistants in South Carolina may prescribe compounded medications within their scope of practice. Prescribing a compounded peptide that lacks FDA approval does not automatically constitute unprofessional conduct under South Carolina law, provided the prescriber has a legitimate clinical relationship with the patient, documents medical necessity, and practices within established clinical standards.

A prescriber who prescribes AOD-9604 without an individualized clinical assessment, or who has a financial relationship with the compounding pharmacy that creates a conflict, could face board scrutiny. That is a professional accountability issue, not a criminal one for the patient.

Is It Legal for You as a Patient?

Receiving a compounded peptide via a valid prescription from a licensed SC prescriber, dispensed by a licensed compounding pharmacy, is legal for you as a patient in South Carolina. You are not purchasing an unapproved drug from an illegal channel. You are receiving a compounded preparation through the existing federal-state regulatory framework that governs all compounded medications.

The legal exposure, if any exists, sits with the prescriber and the pharmacy, not the patient.

How to Access AOD-9604 Legally in South Carolina

There are three realistic pathways for a South Carolina woman to access AOD-9604 through legal channels.

Pathway 1: In-Person Functional Medicine or Obesity Medicine Clinic

South Carolina has a growing number of functional medicine, anti-aging, and obesity medicine clinics that prescribe peptide therapies. An in-person visit allows a full metabolic workup, body composition assessment, and the kind of individualized clinical documentation that supports appropriate prescribing. Look for physicians board-certified in obesity medicine (ABOM) or reproductive endocrinologists who also manage metabolic health.

Pathway 2: Telehealth Prescribers Licensed in South Carolina

Telehealth prescribing of compounded medications including peptides is legal in South Carolina when the prescriber is licensed in the state and has established a valid patient-provider relationship. This typically requires a synchronous video visit, not just an online questionnaire. A prescription generated from an asynchronous questionnaire only may not meet the standard for a valid prescription under SC law.

A telehealth provider should conduct a comprehensive intake including current medications, metabolic labs, menstrual and hormonal history, and contraception status before prescribing AOD-9604.

Pathway 3: Women's Telehealth Platforms With In-State Prescribers

Platforms like WomanRx that hold licensure in South Carolina can connect you with a women's health NP or physician who reviews your labs, hormonal status, and weight history before prescribing. This pathway is particularly well-suited for women in perimenopause or with PCOS because the prescriber can contextualize AOD-9604 within a broader hormonal and metabolic picture rather than treating weight in isolation.

What a Legitimate Prescription Requires

A valid AOD-9604 prescription in South Carolina should include:

• Your full name and date of birth
• The compound name, concentration, and form (typically 1 mg per vial, lyophilized powder for subcutaneous injection)
• Dosing instructions
• Quantity and refills
• Prescriber name, license number, and DEA number if applicable
• Date of issue

The compounding pharmacy will prepare each batch according to USP 797 sterile compounding standards and should provide a certificate of analysis showing potency and sterility testing results. You may request this document and a legitimate pharmacy will provide it.

AOD-9604 and Women's Physiology: What the Evidence Says

The following framework for thinking about AOD-9604 across women's life stages does not appear in any existing clinical guideline. It is based on extrapolation from the available pharmacology, the Heffernan trial data, and established endocrinology of female aging. No trial has tested AOD-9604 specifically in any female-defined subgroup.

Reproductive Years (Ages 18 to 40)

During reproductive years, women have relatively higher growth hormone pulse frequency than men of the same age, a difference driven by estradiol's stimulation of pituitary GH release. The theoretical rationale for adding an exogenous GH fragment is weaker in this life stage. Women in this group who are considering AOD-9604 for weight management should first be screened for PCOS, hypothyroidism, and insulin resistance, all of which have established first-line treatments with far more evidence behind them.

For women with PCOS specifically, the primary metabolic interventions remain lifestyle modification, metformin, and GLP-1 receptor agonists where appropriate. ASRM guidelines on PCOS management do not mention peptide therapies because no evidence base exists.

Trying to Conceive and Pregnancy

AOD-9604 is contraindicated in pregnancy. See the full Pregnancy and Lactation section below.

If you are actively trying to conceive, the prudent position is to stop AOD-9604 before attempting pregnancy. The washout period for subcutaneous peptides of this molecular size is short (hours to days based on pharmacokinetic modeling), but the absence of human teratogenicity data means there is no established safe window.

Perimenopause (Approximately Ages 45 to 52)

This is the life stage where the theoretical case for AOD-9604 is strongest from a physiologic standpoint. Perimenopause brings declining estradiol, disrupted sleep architecture (which itself suppresses GH secretion), and a pronounced shift toward central adiposity. Visceral fat accumulation accelerates significantly in the perimenopause transition, independent of total caloric intake changes. If AOD-9604 preferentially targets lipolysis in visceral adipose tissue, perimenopausal women might theoretically see the most benefit.

The clinical reality is that no perimenopausal-specific trial exists. Providers prescribing AOD-9604 in this life stage are extrapolating from the mixed-sex Heffernan data and mechanism of action. That extrapolation may be reasonable, but you should hear it named as extrapolation, not stated as proven.

Perimenopause is also the life stage where hormonal contraception needs are highest if pregnancy is not desired. If you are perimenopausal and sexually active with pregnancy possible, reliable contraception is required before starting AOD-9604 given the absence of pregnancy safety data.

Postmenopause

Postmenopausal women have the lowest endogenous GH secretion of any female life stage. The mechanistic argument for supplementing with a GH-mimetic fragment is plausible. The evidence is entirely absent. No published trial has enrolled a postmenopausal-only cohort. Bone health is also a relevant consideration in this group: the full growth hormone axis supports bone remodeling, and long-term effects of a partial GH-fragment on bone turnover markers in postmenopausal women have not been studied.

Pregnancy, Lactation, and Contraception

This section is required reading before you start AOD-9604.

Pregnancy

AOD-9604 has no assigned FDA pregnancy category because it was never approved as a drug. Human safety data in pregnancy does not exist. Animal data from growth-hormone-related peptide research raises concern about interference with fetal growth signaling, though AOD-9604's lack of full GH receptor binding reduces but does not eliminate theoretical risk.

The position you should take: treat AOD-9604 as contraindicated in pregnancy. If you discover you are pregnant while using AOD-9604, stop immediately and contact your obstetric provider. There is no data to reassure you, and there is no data to quantify the risk. That uncertainty itself is the reason for the contraindication.

ACOG's framework for evaluating medication safety in pregnancy emphasizes that absence of evidence is not evidence of safety.

Lactation

Subcutaneous peptides can appear in breast milk. AOD-9604 transfer into human breast milk has not been studied. Infant oral bioavailability of peptides is low due to GI proteolysis, but neonatal gut permeability is higher than in adults, meaning transfer to the infant circulation is not zero. The conservative position is to avoid AOD-9604 during lactation. If you are postpartum and considering it, discuss with your provider after weaning.

Contraception Requirement

If you are of reproductive age and using AOD-9604, use reliable contraception. Options with the highest efficacy include hormonal IUDs, copper IUDs, implants, or combined oral contraceptives if you have no contraindications to estrogen. Condoms alone are not adequate given their typical-use failure rate of approximately 13% per year.

Who Is a Reasonable Candidate and Who Is Not

Women Who May Be Appropriate Candidates

• Perimenopausal or postmenopausal women with documented visceral adiposity who have not responded adequately to lifestyle interventions and who do not have contraindications to peptide therapy
• Women with a BMI <40 who are not candidates for or who prefer not to use GLP-1 receptor agonists
• Women whose providers have documented a clinical rationale and have ordered baseline metabolic labs

Women Who Should Not Use AOD-9604

• Pregnant women or women planning pregnancy within the near term
• Breastfeeding women
• Women with a personal or strong family history of cancer, particularly hormonally sensitive cancers, until more long-term safety data exist
• Women with active thyroid disease that is not yet stable (thyroid status affects GH secretion and interpretation of any GH-adjacent therapy)
• Women purchasing from non-pharmacy research chemical sources

What to Ask Your Prescriber Before Starting

A provider prescribing AOD-9604 responsibly should be able to answer these questions without hesitation:

1. What compounding pharmacy are you using, and can I see their USP 797 compliance documentation?
2. What monitoring will we do during treatment (body composition, fasting glucose, IGF-1 levels)?
3. What is the stopping criteria if I am not responding?
4. What is your plan if I develop side effects such as injection site reactions, fluid retention, or joint discomfort?
5. Has this pharmacy had any FDA warning letters?

If a provider cannot answer questions 1 and 2, consider that a signal to seek a second opinion.

Monitoring and What to Track

If you and your provider decide to proceed with AOD-9604, the following baseline and follow-up labs are reasonable based on the mechanism of action and the side-effect profile observed in the Heffernan trial:

| Timepoint | Tests | |-----------|-------| | Baseline | Fasting glucose, HbA1c, insulin, IGF-1, CMP, CBC, TSH, fasting lipid panel, body composition (DEXA or BIA) | | 6 weeks | Fasting glucose, injection site assessment, symptom review | | 12 weeks | Full panel repeat, body composition repeat |

The Heffernan trial ran for 12 weeks and found the 1 mg daily dose to be the most effective without statistically significant adverse metabolic effects. Using that trial as a benchmark, 12 weeks is a reasonable initial treatment period after which you and your provider reassess whether continued use is warranted.